Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of inhaled SNG001 in mechanically ventilated patients with respiratory viral lung infection
ISRCTN30482473Phase 2Completed
- Sponsor
- Synairgen
- Start
- Dec 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of interferon beta-1a in Respiratory viral illness (6 arms), sponsored by Synairgen. Primary endpoints: Occurrence and severity of adverse events and serious adverse events and All-cause mortality by day 28. Started Dec 2025; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
Respiratory viral illness
Beyond the preview
Go deeper on ISRCTN30482473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30482473.